Atleasttwoclinicalcasessuggestedthepotentialimplication of adjusting treatment according to the suggested primary. The first patient, a 50-year-old woman (patient 1, table 1), presented with a swollen left inguinal lymph node. Thebiopsyspecimenrevealedanundifferentiatedcarcinoma, ck7-, ck20-, RE-, PS100-, EMA-(07/2008). The CupPrint suggested the diagnosis of breast cancer, melanoma, or oral carcinoma.Sheunderwentaninguinaldissectionthatshowed a metastasis from melanoma (PS100 and vimentin positive). Thedermatologicalexaminationrevealedalesionoftheskin ontheleftknee.Surgicalexcisionandhistologyconfirmedthe diagnosis of a superficial melanoma, SSM level 2, 0.44 mm deep.Thepatientisstillinremission.
The second case, a 63-year-old woman, presented with swollen left supra-clavicular, mediastinal and axillary lymph nodes(patient2,table1).Theaxillarylymphnodedissection revealedanepidermoidcarcinoma(ck7+,20-).TheCupPrint
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Schlüsselwörter Karzinom bei unbekanntem Primärtumor, Diagnose · Genexpression Carcinomasofanunknownprimarysite(CUP)rankamong the 10 most frequent cancers worldwide and its prognosis is notoriously poor with median survival rates attaining 8months [1] .CUPareheterogeneoustumorswhoseoriginis unidentifiableatthetimeofthediagnosisbuttheysharethe unique clinical feature of metastatic disease. New molecular diagnosistoolswithDNAarraycouldbeapromisingtechnologyinthesearchoflostCUPorigins [2, 3] .Usingthislarge database, Horlings developed a diagnostic gene expression based classifier (CupPrint ® , Agendia BV, Amsterdam, The Netherlands)inordertodiagnosethehistogenicbackground ofCUPindailypractice [4] .TheCupPrintassaywas,atthe timeofthestudy,commercializedbyAgendia.
WereportheretheresultsofaprospectivestudyoffeasibilityconductedbytheGEFCAPI(Grouped'EtudeFrançais des Carcinomes de site Primitif Inconnu), in collaboration withtheAgendiateam [4] .Theaimofthisstudywastoevaluate the feasibility of integrating an oligonucleotide microarray, that contains 495 genes selected as highly differentially expressedbetween49tumortypes(CupPrint).Thesample's gene expression profile is compared to a previously built tumor gene expression data set encompassing 49 primary tumor types to identify the tissue of origin in patients with CUP. Formalin-fixed, paraffin-embedded (FFPE) specimens from diagnostic biopsies of 22 patients with CUP were prospectivelycollected.Theassaywassuccessfullyperformedon Inthepresentstudy,weshowedthatCupPrintdiagnosisis feasibleindailypracticewithoutdelayingtreatment,andmay change the chemotherapy regimen and clinical management inmorethan50%ofpatients.Thisnewdiagnosistoolcould improve the prognosis in CUP patients, as suggested by Bridgewateretal. [5] .Thefeasibilityofintegratingageneexpression analysis allowed us to elaborate the GEFCAPI-04 trial. This randomized phase III trial is planned to compare therapy based on gene expression-suspected primary cancer versus empiric chemotherapy. The main objective will be to demonstrateabenefitinprogressionfreesurvivalinpatients receiving'individualized'treatment,includingchemotherapy andtargetedtherapies.
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